^
Association details:
| Biomarker: | High NLR |
|---|---|
| Cancer: | HER2 Positive Breast Cancer |
| Drug: | Irene (pyrotinib) (EGFR inhibitor, HER2 inhibitor, HER4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Association between platelet-to-lymphocyte ratio and outcomes in HER2-positive advanced breast cancer patients treated with pyrotinib: a retrospective study
Published date:
10/31/2023
Excerpt:
This was a retrospective cohort study including 156 HER2-positive advanced BC patients who treated with pyrotinib...Low PLR was associated with better disease control rate (P=0.005)….For overall survival (OS), univariate analysis showed that high NLR (P=0.001), MLR (P=0.005), PLR (P<0.001), or PIV (P=0.018), more than two metastatic sites (P=0.001), presence of liver metastasis (P=0.004) or brain metastasis (P=0.007), and pyrotinib monotherapy (P=0.036) were associated with worse OS.
DOI:
10.21037/tcr-23-1078
